SUPRICORT 0.025%W/W CREAM

Indications

• Eczema
• Psoriasis
• Contact dermatitis
• Allergic dermatitis
• Seborrheic dermatitis

Dosage

Children: Refer to specific product information or clinical guidelines for appropriate dosing in children, as it varies by formulation and condition treated.

Adults: Refer to specific product information or clinical guidelines for appropriate dosing, as it varies by formulation and condition treated.

Mechanism of action

Acetonide exerts its effects by binding to glucocorticoid receptors in the cytoplasm of target cells, leading to the translocation of the receptor-ligand complex into the nucleus. This complex then influences the expression of specific genes, resulting in decreased production of pro-inflammatory cytokines and increased production of anti-inflammatory proteins. This modulation of gene expression contributes to its anti-inflammatory and immunosuppressive effects.

Pharmacodynamics

The pharmacodynamics of acetonide involve its ability to inhibit the migration of leukocytes to sites of inflammation, reduce the production of inflammatory mediators such as prostaglandins and leukotrienes, and suppress the immune response. The potency and duration of action can vary based on the specific formulation and concentration used.

Pharmacokinetics

Acetonide is absorbed through the skin when applied topically, with systemic absorption depending on the formulation, application area, and duration of use. It undergoes hepatic metabolism, and its metabolites are excreted primarily through the urine. The half-life and clearance rates can vary based on individual patient factors and specific formulations.

Contra-indications

• Hypersensitivity to acetonide or any component of the formulation.
• Active or untreated infections at the site of application.

Adverse effects

• Local irritation or burning sensation at the application site.
• Skin thinning or atrophy with prolonged use.
• Systemic effects such as adrenal suppression with high doses or prolonged therapy.

Interactions

• Increased risk of systemic effects when used with other corticosteroids.
• Potentially altered metabolism when administered with CYP3A4 inhibitors or inducers.

Precautions

• Use with caution in patients with a history of tuberculosis or other infections.
• Monitor for signs of adrenal insufficiency in patients on high doses.
• Avoid application to large areas of the body or under occlusive dressings.

Pregnancy

Acetonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult with a healthcare professional before use.

Breast-feeding

Limited data available. Use with caution as it may be excreted in breast milk. Consult with a healthcare professional before use.

Storage

Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Topical cream
• Topical ointment
• Topical solution

Indications

• Atopic dermatitis
• Psoriasis
• Contact dermatitis
• Seborrheic dermatitis
• Allergic rhinitis
• Asthma
• Eczema

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations for pediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated and the formulation used.

Mechanism of action

Flucinolone exerts its effects by binding to glucocorticoid receptors in the cytoplasm of target cells. This receptor-ligand complex translocates to the nucleus, where it regulates the expression of genes involved in inflammation and immune response. The anti-inflammatory action is primarily due to the inhibition of pro-inflammatory cytokines, suppression of leukocyte infiltration, and stabilization of lysosomal membranes.

Pharmacodynamics

The pharmacodynamics of flucinolone involve its ability to modulate the immune response and decrease inflammation. It reduces the production of inflammatory mediators such as prostaglandins and leukotrienes, leading to decreased redness, swelling, and pain associated with inflammatory conditions. Additionally, flucinolone has an impact on metabolism, influencing glucose levels and protein synthesis in target tissues.

Pharmacokinetics

Flucinolone is typically well-absorbed when applied topically, with systemic absorption varying based on the formulation and the site of application. It is metabolized predominantly in the liver, and the metabolites are excreted primarily via the kidneys. The half-life of flucinolone can be influenced by factors such as the route of administration and individual patient characteristics.

Contra-indications

• Hypersensitivity to flucinolone or any component of the formulation
• Active infections (viral, bacterial, or fungal) in the area to be treated
• Rosacea or perioral dermatitis

Adverse effects

• Skin thinning or atrophy
• Telangiectasia
• Striae
• Burning or itching at the site of application
• Systemic absorption leading to adrenal suppression (with prolonged use)

Interactions

• May enhance the effects of other topical corticosteroids
• Caution with concurrent use of other immunosuppressive agents

Precautions

• Use with caution in patients with a history of hormonal disorders
• Monitor for signs of local or systemic infection
• Avoid prolonged use on large surface areas or under occlusive dressings

Pregnancy

Flucinolone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Systemic absorption may occur, which poses risks.

Breast-feeding

Caution is advised when using flucinolone while breastfeeding. It is recommended to avoid application on the breast unless necessary.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Topical cream
• Topical ointment
• Topical solution
• Topical lotion